# A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Source: https://onco.cc/trials/nct05261269/  
OnCo record `nct05261269` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DAN-222 run by Dantari, Inc., completed.

## Summary

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer is a phase 1 interventional study registered as NCT05261269 by Dantari, Inc., with 30 participants enrolled, started 2022-02-02. Conditions recorded: HER2-negative Metastatic Breast Cancer. Interventions recorded: DAN-222 and Niraparib.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05261269
- Phase: 1
- Setting: A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
- Sponsor: Dantari, Inc.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05261269: https://clinicaltrials.gov/study/NCT05261269

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [DAN-222](https://onco.cc/drugs/dan-222/)
- companies: [Dantari](https://onco.cc/companies/dantari/)

---
JSON: https://onco.cc/api/v1/entities/nct05261269.json